| Ident. | Authors (with country if any) | Title |
|---|
| 000353 (2008) |
J. C. Sharma [Royaume-Uni] ; I. N. Ross [Royaume-Uni] ; O. Rascol [France] ; D. Brooks [Royaume-Uni] | Relationship between weight, levodopa and dyskinesia: the significance of levodopa dose per kilogram body weight |
| 000805 (2001) |
Alberto Albanese [Italie] ; Ubaldo Bonuccelli [Italie] ; Christine Brefel [France] ; K. Ray Chaudhuri [Royaume-Uni] ; Carlo Colosimo [Italie] ; Tobias Eichhorn [Allemagne] ; Eldad Melamed [Israël] ; Pierre Pollak [France] ; Teus Van Laar [Pays-Bas] ; Mario Zappia [Italie] | Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease |
| 000808 (2001) |
Jean-Louis Montastruc [France] ; Karine Desboeuf [France] ; Maryse Lapeyre-Mestre [France] ; Jean-Michel Senard [France] ; Olivier Rascol [France] ; Christine Brefel-Courbon [France] | Long‐term mortality results of the randomized controlled study comparing bromocriptine to which levodopa was later added with levodopa alone in previously untreated patients with Parkinson's disease |
| 000C72 (2008) |
P. Damier [France] ; F. Viallet [France] ; M. Ziegler [France] ; I. Bourdeix [France] ; K. Rerat [France] | Levodopa/DDCI and entacapone is the preferred treatment for Parkinson’s disease patients with motor fluctuations in routine practice: a retrospective, observational analysis of a large French cohort |
| 000D02 (2007) |
Sonja Krösser [Allemagne] ; Roland Neugebauer [Allemagne] ; Didier Chassard [France] ; Andreas Kovar [Allemagne] | Investigation of the impact of sarizotan on the pharmacokinetics of levodopa |
| 000E14 (2002) |
Marie-Paule Muriel [France] ; Gaël Orieux [France] ; Etienne C. Hirsch [France] | Levodopa but not ropinirole induces an internalization of D1 dopamine receptors in parkinsonian rats |
| 000E29 (2004) |
Jan C. M. Zijlmans [Royaume-Uni, Pays-Bas] ; Berengere Debilly [France] ; Olivier Rascol [France] ; Andrew J. Lees [Royaume-Uni] ; Franck Durif [France] | Safety of entacapone and apomorphine coadministration in levodopa‐treated Parkinson's disease patients: Pharmacokinetic and pharmacodynamic results of a multicenter, double‐blind, placebo‐controlled, cross‐over study |
| 001085 (2005) |
Christine Brefel-Courbon [France] ; Pierre Payoux [France] ; Claire Thalamas [France] ; Fabienne Ory [France] ; Isabelle Quelven [France] ; François Chollet [France] ; Jean Louis Montastruc [France] ; Olivier Rascol [France] | Effect of levodopa on pain threshold in Parkinson's disease: A clinical and positron emission tomography study |
| 001160 (2006) |
Aurélie Funkiewiez [France] ; Claire Ardouin [France] ; Roshan Cools [Royaume-Uni] ; Paul Krack [France] ; Valérie Fraix [France] ; Alina Batir [France] ; Stephan Chabardès [France] ; Alim-Louis Benabid [France] ; Trevor W. Robbins [Royaume-Uni] ; Pierre Pollak [France] | Effects of levodopa and subthalamic nucleus stimulation on cognitive and affective functioning in Parkinson's disease |
| 001201 (1990) |
F. Javoy-Agid [France] ; E. C. Hirsch [France] ; S. Dumas [France] ; C. Duyckaerts [France] ; J. Mallet [France] ; Y. Agid [France] | Decreased tyrosine hydroxylase messenger RNA in the surviving dopamine neurons of the substantia nigra in parkinson's disease: An in situ hybridization study |
| 001245 (2009) |
A. H. Schapira [Royaume-Uni] ; Y. Agid [France] ; P. Barone [Italie] ; P. Jenner [Royaume-Uni] ; M. R. Lemke [Allemagne] ; W. Poewe [Autriche] ; O. Rascol [France] ; H. Reichmann [Allemagne] ; E. Tolosa [Espagne] | Perspectives on recent advances in the understanding and treatment of Parkinson’s disease |
| 001262 (2006) |
Olivier Rascol [France] ; David J. Brooks [Royaume-Uni] ; Amos D. Korczyn [Israël] ; Peter P. De Deyn [Belgique] ; Carl E. Clarke [Royaume-Uni] ; Anthony E. Lang [Canada] ; Mona Abdalla [Royaume-Uni] | Development of dyskinesias in a 5‐year trial of ropinirole and L‐dopa |
| 001708 (2007) |
Vincent Paillé [France] ; Vincent Henry [France] ; Laurent Lescaudron [France] ; Philippe Brachet [France] ; Philippe Damier [France] | Rat model of Parkinson's disease with bilateral motor abnormalities, reversible with levodopa, and dyskinesias |
| 001839 (2004) |
C. Warren Olanow [États-Unis] ; Yves Agid [France] ; Yoshi Mizuno [Japon] ; Alberto Albanese [Italie] ; U. Bonucelli [Italie] ; Philip Damier [France] ; Justo De Yebenes [Espagne] ; Oscar Gershanik [Argentine] ; Mark Guttman [Canada] ; F. Grandas [Espagne] ; Mark Hallett [États-Unis] ; Ole Hornykiewicz [Autriche] ; Peter Jenner [Royaume-Uni] ; R. Katzenschlager [Royaume-Uni] ; William J. Langston [États-Unis] ; Peter Lewitt [États-Unis] ; Eldad Melamed [Israël] ; M. A. Mena [Espagne] ; P. P. Michel [France] ; Catherine Mytilineou [États-Unis] ; Jose A. Obeso [Espagne] ; Werner Poewe [Autriche] ; Niall Quinn [Royaume-Uni] ; R. Raisman-Vozari [France] ; Ali H. Rajput [Canada] ; Olivier Rascol [France] ; Christina Sampaio [Portugal] ; Fabrizio Stocchi [Italie] | Levodopa in the treatment of Parkinson's disease: Current controversies |
| 001B82 (2010) |
Carine Chassain [France] ; Guy Bielicki [France] ; Cécile Keller [France] ; Jean-Pierre Renou [France] ; Franck Durif [France] | Metabolic changes detected in vivo by 1H MRS in the MPTP‐intoxicated mouse |
| 001C86 (2006) |
Alexandre Castro-Caldas [Portugal] ; Paul Delwaide [Belgique] ; Wolfgang Jost [Allemagne] ; Marcelo Merello [Argentine] ; Adrian Williams [Royaume-Uni] ; Paolo Lamberti [Italie] ; Miguel Aguilar [Espagne] ; Susanna Del Signore [France] ; Pierre Cesaro [France] | The Parkinson–Control study: A 1‐year randomized, double‐blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease |
| 001D03 (2005) |
Christopher G. Goetz [États-Unis] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Cristina Sampaio [Portugal] | Evidence‐based medical review update: Pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004 |
| 001E29 (2001) |
C. Marin [Espagne] ; A. Jiménez [Espagne] ; M. Bonastre [Espagne] ; M. Vila [France, États-Unis] ; Y. Agid [France] ; E. C. Hirsch [France] ; E. Tolosa [Espagne] | LY293558, an AMPA glutamate receptor antagonist, prevents and reverses levodopa‐induced motor alterations in Parkinsonian rats |
| 001F67 (2011) |
Susan H. Fox [Canada] ; Regina Katzenschlager [Autriche] ; Shen-Yang Lim [Malaisie] ; Bernard Ravina [États-Unis] ; Klaus Seppi [Autriche] ; Miguel Coelho [Portugal] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Christopher G. Goetz [États-Unis] ; Cristina Sampaio [Portugal] | The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease |
| 002000 (2006) |
Wolfgang H. Oertel [Allemagne] ; Erik Wolters [Pays-Bas] ; Cristina Sampaio [Portugal] ; Santiago Gimenez-Roldan [Espagne] ; Bruno Bergamasco [Italie] ; Max Dujardin [France] ; Donald G. Grosset [Royaume-Uni] ; Guy Arnold [Allemagne] ; Klaus L. Leenders [Pays-Bas] ; Hans-Peter Hundemer [États-Unis] ; Alberto Lled [États-Unis] ; Andrew Wood [États-Unis] ; Paul Frewer [États-Unis] ; Johannes Schwarz [Allemagne] | Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study |
| 002001 (2007) |
Robert A. Hauser [États-Unis] ; Olivier Rascol [France] ; Amos D. Korczyn [Israël] ; A. Jon Stoessl [Canada] ; Ray L. Watts [États-Unis] ; Werner Poewe [Autriche] ; Peter P. De Deyn [Belgique] ; Anthony E. Lang [Canada] | Ten‐year follow‐up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa |
